Sermorelin vs CJC-1295

Sermorelin vs CJC-1295: a familiar comparison with major evidence gaps.

Sermorelin and CJC-1295 are commonly compared because both are described as growth hormone-releasing hormone analogues. The simple short-acting-versus-long-acting story is incomplete: CJC-1295 can refer to forms with or without a drug-affinity complex, and FDA says online and compounded product descriptions often do not identify the form clearly. FDA has also identified limited clinical data, impurity and immunogenicity concerns, and serious adverse events associated with CJC-1295. This page therefore compares the evidence boundary rather than naming a universal winner.

By Iacob Pastina, Independent Researcher & Publisher · Source checks: September 21, 2026

Two identical glasses side by side, one with clear water and one with pale blue water

This comparison exists because readers search for the distinction. Search demand does not establish that either product works, belongs in the same provider table or should be prescribed. We have audited providers only for the side explicitly linked below.

Key differences between Sermorelin and CJC-1295
Question	Sermorelin	CJC-1295
Product identity	A GHRH(1-29) analogue; current online plans are compounded.	The name can cover forms with or without DAC, which are not interchangeable.
FDA-approved finished product?	No current compounded product is FDA-approved.	No FDA-approved finished drug identified by FDA's review.
Human evidence	Small historical GHRH studies; no longevity proof.	FDA describes available clinical data as limited.
What does this site compare?	Sourced online sermorelin plans.	No CJC-1295 provider ranking yet.

What is the difference between sermorelin and CJC-1295?

Both are discussed as GHRH analogues, but CJC-1295 is not one sufficiently described product in many marketing pages. FDA's review notes that listings may omit whether the material has DAC and which chemical form is used.

A duration claim is therefore not enough to establish product equivalence, quality or an outcome advantage.

Is CJC-1295 FDA-approved?

FDA's compounding evaluation found no approved products containing any form of CJC-1295 in the markets it reviewed and described the available literature as too limited to understand historical compounded use fully.

Current compounded sermorelin products are also not FDA-approved. Historical Geref status does not transfer to them.

Is CJC-1295 stronger or longer-lasting than sermorelin?

Marketing pages frequently frame CJC-1295 as longer-lasting, but the statement depends on the exact form and does not prove a better clinical outcome. FDA notes limited clinical data and product-characterization problems.

This review found no basis for translating a longer signal into a universal recommendation for recovery, body composition or longevity.

Why does this page not rank CJC-1295 providers?

A useful provider ranking requires a verified product identity, comparable route, sourced price, supplied quantity, pharmacy and contract. The current CJC-1295 source set does not support that market table.

The linked sermorelin comparison is narrower: it covers only providers whose public product and payment information has been audited.

Which sources support this comparison?

These sources were checked September 21, 2026. They define the product, population and regulatory boundaries used above; they do not determine individual suitability.

Continue with another evidence comparison.

We publish a comparison when people are searching for the distinction, even when only one side has audited providers. Inclusion is not an endorsement.

01 / Evidence comparison